Arcellx Inc (ACLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arcellx Inc (ACLX) has a cash flow conversion efficiency ratio of -0.145x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-58.17 Million) by net assets ($402.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Arcellx Inc (ACLX) total market value for the company's overall valuation and market capitalisation.
Arcellx Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Arcellx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Arcellx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcellx Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Arcellx Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ISS A/S
CO:ISS
|
0.070x |
|
ESCO Technologies Inc
NYSE:ESE
|
0.036x |
|
Gaztransport & Technigaz SAS
PA:GTT
|
0.372x |
|
Indian Overseas Bank
NSE:IOB
|
-0.682x |
|
BKW AG
SW:BKW
|
0.024x |
|
Cleveland-Cliffs Inc
NYSE:CLF
|
0.040x |
|
Changjiang Securities Co Ltd
SHE:000783
|
0.350x |
|
Osisko Gold Ro
TO:OR
|
0.059x |
Annual Cash Flow Conversion Efficiency for Arcellx Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Arcellx Inc from 2018 to 2025. View current stock price of Arcellx Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $402.35 Million | $-210.26 Million | -0.523x | -184.74% |
| 2024-12-31 | $454.79 Million | $-83.47 Million | -0.184x | -142.92% |
| 2023-12-31 | $485.38 Million | $207.57 Million | 0.428x | +188.26% |
| 2022-12-31 | $204.95 Million | $-99.30 Million | -0.485x | -208.55% |
| 2021-12-31 | $-121.52 Million | $-54.24 Million | 0.446x | +178.71% |
| 2020-12-31 | $50.54 Million | $-28.66 Million | -0.567x | -198.90% |
| 2019-12-31 | $-32.74 Million | $-18.77 Million | 0.573x | +216.97% |
| 2018-12-31 | $14.00 Million | $-6.86 Million | -0.490x | -- |
About Arcellx Inc
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a prod… Read more